OpGen Signs Supply Agreement to Use Thermo Fisher Scientific’s Technology to Advance Acuitas® Rapid Test
June 19 2017 - 7:00AM
OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into
a global supply agreement to use Thermo Fisher Scientific’s
technology to support the commercialization of its rapid molecular
products and informatics system to help combat multidrug-resistant
infections. OpGen will combine Thermo Fisher’s real-time PCR
solutions with its genomic analysis and bioinformatics technology
to help healthcare providers rapidly and accurately identify
bacterial antibiotic susceptibility using resistance gene profiles.
Under the terms of the agreement, OpGen will
commercialize the Acuitas Rapid Test for Pathogen ID and resistance
genes on Thermo Fisher’s new mid-throughput real-time PCR system.
The effort will be supported by local labs that will be able to
interpret results using customized analysis software and OpGen’s
cloud-based Acuitas Lighthouse® Knowledgebase to match genomic
analysis data with antibiotic susceptibility information to
identify microbial infections in individual patients.
“This effort supports our commitment to advancing
the latest in molecular testing to help hospitals and health
systems rapidly and accurately streamline protocols for informed
decision-making in acute care settings,” said Evan Jones, Chairman
and CEO of OpGen. “Thermo Fisher’s market leading position in PCR,
its global install base makes them an ideal partner for our Acuitas
Rapid Test.”
About OpGenOpGen,
Inc. is harnessing the power of informatics and genomic
analysis to provide complete solutions for patient, hospital and
network-wide infection prevention and treatment. Learn more
at www.opgen.com and follow OpGen on Twitter
and LinkedIn.
OpGen, Acuitas, Acuitas Lighthouse and
QuickFISH are registered trademarks of OpGen, Inc.
Forward-Looking StatementsThis
press release includes statements relating to OpGen’s Acuitas Rapid
Test in development and its Acuitas Lighthouse Knowledgebase in
development, its commercialization plans for these products, and
its efforts to seek regulatory clearance for such products. These
statements and other statements regarding OpGen’s future plans and
goals constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, our ability to successfully, timely and
cost-effectively develop, seek and obtain regulatory clearance for
and commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, the success of our commercialization efforts,
the effect on our business of existing and new regulatory
requirements, and other economic and competitive factors. For a
discussion of the most significant risks and uncertainties
associated with OpGen's business, please review our filings with
the Securities and Exchange Commission (SEC). You are cautioned not
to place undue reliance on these forward-looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor and Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Apr 2024 to May 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From May 2023 to May 2024